Atrial cardiomyopathy: markers and outcomes. Read more in the @EHJ at doi.org/10.1093/eurhea… #AtrialCardiomyopathy #CardiomyopathyAwareness #CardiologyResearch @ESCardio European Society of Cardiology Journals

🫀 Arrhythmogenic Cardiomyopathy or “Athlete’s Heart”?: A Systematic Approach to Differential Diagnosis JACC Journals #Cardiology #CardioEd

In Nature Medicine - looking at AB-1002 phase I trial, 2 doses, 11 patients. nature.com/articles/s4159…

New event at #AHA2025! GPM Symposium Model Systems: Preclinical to Phase I Bridge Nov 7 12:30-5:15 Learn state-of-the-art systems to bridge therapies from the Preclinical to Phase I trials Speakers: Kricket Seidman, Joe Wu, Kiran Musunuru, Vicki Parikh, Eric Adler, and more!

🫀 Why do arrhythmogenic cardiomyopathy hearts develop fattyfibro remodeling? We used patient-derived iPSC epicardial cells lacking PKP2 to uncover how the outer layer of the heart can drive this pathological remodeling.👇 nature.com/articles/s4200… BIO5 Institute UA College of Medicine – Tucson

Italy 🇮🇹 + #cardiomyopathies? Unbeatable combo! 🧬🫀🍝🍹 1️⃣ month until European Society of Cardiology M&PD 2025 in Trieste!❗️🗓 Early fee registration until tomorrow 31/10: ow.ly/uHIt50Xg98v Alessia Argiró Massimo Imazio Silvia Castelletti Giorgia Panichella Pablo Garcia-Pavia Maurizio Pieroni francesca graziani_FG

Genetic testing in early-onset atrial fibrillation uncovers a high rate of pathogenic variants and changes clinical care. Read more in #EHJ. doi.org/10.1093/eurhea… #PrecisionCardiology #cardiotwitter European Society of Cardiology Journals European Society of Cardiology

What if your genes could predict a life-threatening condition before symptoms ever appear? Explore how medical science uncovered the genetic roots of thoracic aortic aneurysm & why that discovery changed everything. Tune in to this #ACCEL Lite episode ➡️ bit.ly/43awVZg

Ojooo. Yo ya he diagnosticado varias arritmias con estos dispositivos

SIMULTANEOUS PUBLICATION AT #AHA25 🔥 First-in-human study of TN-201, an AAV9 gene replacement therapy in MYBPC3-associated hypertrophic cardiomyopathy Explore initial safety, pharmacodynamic, & imaging results from MyPEAK-1 doi.org/10.1093/cvr/cv… #CVD #CardiovascularResearch

Today, Milind Desai MD MBA shared new interim clinical data on MyPEAK™-1 Phase 1b/2 clinical trial for TN-201 at #AHA25. Missed it? Tune into our webcast on Monday (11/10) at 8 am EST. Details in our press release: bit.ly/4nIOfMg #GeneTherapy #HeartDisease

Ambulatory ECG monitoring predicts malignant arrhythmic events in genetic DCM, especially with LMNA, FLNC, TTNtv variants. Gene-specific patterns emerge — maybe time to move beyond “genetic vs non-genetic”? #CardioGenomics #DCM #Arrhythmia #ECG #Europace academic.oup.com/europace/advan…

🚨 #AHA2025- CorCMR study: In patients with chest pain + non-obstructive coronary arteries, stress #whyCMR diagnosed microvascular angina in 50% vs <1% with angiogram alone. QoL improved 22 vs <1 point at 1 year. Read more: shorturl.at/JymI9 American College of Cardiology JACC Journals

Really cool article on 12-Lead Electrocardiographic #Anatomy Understanding cardiac anatomy is the key for understanding #POCUS as well. 🔗 jacc.org/doi/10.1016/j.… #FOAMed #MedEd

Update on the efficacy and safety of Nex-Z in ATTR-CM from the phase 1 program #AHA2025 #CardioTwitter The phase III is on hold pending evaluation of liver-related safety events #MedIQAHA25

(1/14) 🚨I had the privilege of providing commentary on the Phase 2 #coramitug trial at #AHA25. The headline was that patients who received high-dose (60 mg/kg) coramitug had significant reductions in NT-proBNP at 1 year compared with placebo. So it’s an unequivocal win, right?

1) Welcome to a new CE/#CME-accredited #tweetorial with updates from #AHA2025 on gene silencer therapeutics for #ATTR_CM. A couple years ago we had no specific tx for ATTR, and now our proverbial cup runneth over! #cardiotwitter #cardioX #MedEd

(1/4) Although women now make up nearly half of medical school graduates, fewer than 20% of cardiologists are women - and an even smaller proportion hold senior or leadership roles. #WomenInCardiology

🚀 Big regulatory shift: The FDA’s new “Plausible Mechanism Pathway” for truly personalised therapies The FDA, via Marty Makary and Vinay Prasad, has introduced a new regulatory route that will allow life-changing, tailor-made treatments to reach patients faster—especially when

1) Welcome to a new #accredited #tweetorial with more highlights from the #AHA25 congress! Here we address new data on the management of #myocardial #TTR #amyloidosis, or #ATTR_CM, with a focus on gene #stabilizer therapies.